Determination of clinical outcome and pharmacoeconomics of anti-rheumatoid arthritis therapy using CDAI, EQ-5D-3L and EQ-VAS as indices of disease amelioration

Asian Pacific Journal of Tropical Disease

Volumn 2, Issue SUPPL2, 2012, Pages

  Ghosh, Pinaki ^b   Kandhare, Amit Dattatray ^b   Kumar, V Shiva ^b   Rajmane, Anuchandra Ramchandra ^b   Adil, Mohammad ^b   Bodhankar, Subhash Laxman ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

^b NONE

Author keywords

Arthritis; CDAI; EQ 5D 3L; EQ VAS; Pharmacoeconomics

Indexed keywords

CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DRUG COST; EPIGASTRIC PAIN; FECES; HUMAN; INTERVIEW; LONGITUDINAL STUDY; MONOTHERAPY; NAUSEA; OPEN STUDY; PATIENT CODING; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIDE EFFECT; SWEATING; TREATMENT OUTCOME; VISUAL ANALOG SCALE; WEIGHT FLUCTUATION;

EID: 84871772761     PISSN: 22221808     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2222-1808(12)60242-4     Document Type: Article

References (73)

1. Benucci M, Saviola G, Baiardi P, Manfredi M, Sarzi Puttini P, Atzeni F Determinants of Risk Infection During Therapy with Anti TNF-Alpha Blocking Agents in Rheumatoid Arthritis. Open Rheumatol J 2012, 6:33-37.
2. Ghosh P, Bhise KS, Paradkar AR, Bodhankar SL, Kadam SS Reduced Ulcerogenic Potential and Anti-arthritic Effect of Chitosan-Naproxen Sodium Complexes. AAPS PharmSciTech 2012, [Epub ahead of print] DOI: 10.1208/S12249-012-9779-2.
3. Senolt L, Vencovský J, Pavelka K, Ospelt C, Gay S Prospective new biological therapies for rheumatoid arthritis. Autoimmun Rev 2009, 9(2):102-107.
4. Patil MVK, Kandhare AD, Bhise SD Anti-arthritic and anti-inflammatory activity of Xanthium srtumarium L. ethanolic extract in Freund's complete adjuvant induced arthritis. Biomed Aging Pathol 2012, 2:6-15.
5. Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A, et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2008, 196:756-763.
6. Scire C, Montecucco C, Codullo V, Epis O, Todoerti M, Caporali R Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power doppler signal predicts short-term relapse. Rheumatol 2009, 48:1092-1097.
7. Lee DM, Schur PH Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 2003, 62:870-874.
8. Chen H, Shoumura S, Emura S, Isono H Tibetan Medicated-bath therapy may improve adjuvant arthritis in rat. Evid Based Compl Alt Med 2009, 6(2):211-217.
9. Dale J, Porter D Pharmacotherapy: concepts of pathogenesis and emerging treatments. Optimising the strategy of care in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2010, 24(4):443-455.
10. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010, 56:1113-1132.
11. Yazici Y, Bergman M, Pincus T Time to score quantitative rheumatoid arthritis measures: 28-Joint Count, Disease Activity Score, Health Assessment Questionnaire (HAQ), Multidimensional HAQ (MDHAQ), and Routine Assessment of Patient Index Data (RAPID) scores. J Rheumatol 2008, 35:603-609.
12. Gosavi TP, Kandhare AD, Raygude KS, Ghosh P, Bodhankar SL Evaluation of clinical outcome in arthritis with AIMS2. Deccan J Pharmacol 2011, 2(3):10-30.
13. Ghosh A, Ghosh B, Pain S, Pande A, Saha S, Banerjee A, Biswas AB Comparison between DAS28, CDAI and HAQ-DI as tools to monitor early rheumatoid arthritis patients in eastern India. Indian J Rheumatol 2011, 6:116-122.
14. Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Llorca J Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy. Ann N Y Acad Sci 2010, 1193:153-159.
15. Hermansson M, Artemenko K, Ossipova E, Eriksson H, Lengqvist J, Makrygiannakis D, et al. MS analysis of rheumatoid arthritic synovial tissue identifies specific citrullination sites on fibrinogen. Proteomics Clin Appl 2010, 4:511-518.
16. Ghosh P, Kandhare AD, Gauba D, Raygude KS, Bodhankar SL Determination of efficacy, adverse drug reactions and cost effectiveness of three triple drug regimens for the treatment of H. pylori infected acid peptic disease patients. Asian Pac J Trop Biomed 2012, In press.
17. Gosavi TP, Kandhare AD, Raygude KS, Ghosh P, Bodhankar SL A comparative study on the efficacy, safety and cost effectiveness of Viscum album and Rauwolfia serpentina mother tincture in hypertensive patients. Deccan J. Natural Products 2011, 2(3):29-35.
18. Kandhare AD, Raygude KS, Ghosh P, Ghule AE, Bodhankar SL Neuroprotective effect of naringin by modulation of endogenous biomarkers in streptozotocin induced painful diabetic neuropathy. Fitoterapia 2012, 83:650-659.
19. Raygude KS, Kandhare AD, Ghosh P, Gosavi TP, Bodhankar SL Consumption of Alcohol and H. pylori infection: A Cumulative Meta-Analysis of Literature. Asian J Biochem Pharm Res 2011, 3(1):338-345.
20. Kandhare AD, Raygude KS, Ghosh P, Bodhankar SL The ameliorative effect of fisetin, a bioflavonoid, on ethanol-induced and pylorus ligation-induced gastric ulcer in rats. Int J Green Pharm 2011, 5:236-243.
21. Badgujar LB, Ghosh P, Gaur V, Bodhankar SL Effect of petroleum ether extract of Sphaeranthus indicus linn. on complete freund's adjuvant induced arthritis in laboratory rats. Pharmacologyonline 2009, 2:281-291.
22. Kandhare AD, Raygude KS, Ghosh P, Gosavi TP, Bodhankar SL Patentability of Animal Models: India and the Globe. Int J Pharm Biol Arc 2011, 2(4):1024-1032.
23. Jahagirdar K, Ghosh P, Adil SM, Ziyaurrahman AR Effect of hydroalcoholic extract of Psidium guyava linn. on complete freund's adjuvant induced arthritis in laboratory animals. Pharmacologyonline 2010, 3:706-719.
24. Patil MVK, Kandhare AD, Bhise SD Anti-inflammatory effect of Daucus carota root on experimental colitis in rats. Int J Pharm Pharm Sci 2012, 4(1):337-343.
25. Lee JH, Kim GH Evaluation of antioxidant and inhibitory activities for different subclasses flavonoids on enzymes for rheumatoid arthritis. J Food Sci 2010, 75(7):H212-H217.
26. Kavanaugh A, Heudebert G, Jain R, Cush J Cost Evaluation of Novel Therapeutics in Rheumatoid Arthritis (CENTRA): A decision analysis model. Seminar Arthritis Rheum 1996, 25:297-307.
27. Bansback N, Ara R, Karnon J, Anis A Economic evaluations in rheumatoid arthritis: a critical review of measures used to define health States. Pharmacoeconomics 2008, 26:395-408.
28. Shini VK, Aboobacker S, Pahuja S, Revikumar KG, Bhasi R Pharmacoeconomic study of DMARDs in the management of rheumatoid arthritis. Int J Pharm Sci Rev Res 2010, 5:148-54.
29. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
30. Stagakis I, Bertsias G, Karvounaris S, Kavousanaki M, Virla D, Raptopoulou A, et al. Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther 2012, 14(3):R141.
31. Varani K, Massara A, Vincenzi F, Tosi A, Padovan M, Trotta F, Borea PA Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha but not methotrexate. Arthritis Rheum 2009, 60:2880-2891.
32. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011, 306(21):2331-2339.
33. Rabin R, de Charro F EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001, 33:337-343.
34. Shaw JW, Johnson JA, Coons SJ US valuation of the EQ-5D health states: Development and testing of the D1 valuation model. Med Care 2005, 43:203-220.
35. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Therap 2005, 7:706-796.
36. Aletaha D, Smolen J The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005, 23:100-108.
37. Smolen JS, Aletaha D Activity assessments in rheumatoid arthritis. Current Opin Rheumatol 2008, 20:306-313.
38. Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008, 58:964-975.
39. Keystone E, Heijde DV, Mason D, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008, 58:3319-3329.
40. Pratt AG, Isaacs JD, Mattey DL Current concepts in the pathogenesis of early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2009, 23:37-48.
41. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2008, 17(371):1665-1674.
42. Galloway GB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatol (Oxford) 2010, 50(1):124-131.
43. Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S Association between disease modifying anti-rheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 2011, 305:2525-2531.
44. Stanczyk J, Ospelt C, Gay S Is there a future for small molecule drugs in the treatment of rheumatic diseases?. Curr Opin Rheumatol 2008, 20:257-262.
45. Balsa A, de Miguel E, Castillo C, Peiteado D, Martín-Mola E Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power doppler ultasonography as golds standard. Rheumatol 2010, 49:683-690.
46. Ghosh P, Bodhankar SL A Cross Sectional Study to Determine Association of the Socio Demographic Risk Factors with Prevalence and Virulence of H. pylori Infection in Salivary Samples of Asymptomatic Subjects by Application of Polymerase Chain Reaction Technique. Pharmacologia 2012, 3:481-489.
47. Kandhare AD, Raygude KS, Ghosh P, Gosavi TP, Bodhankar SL A comparative cross sectional descriptive study of individual pharmacy Vs mall pharmacies to evaluate customer satisfaction as well as purchasing behavior. Der Pharmacia Lettre 2011, 3(4):71-83.
48. Patil MVK, Kandhare AD, Bhise SD, Bhale S A comparative cross sectional descriptive market survey of various brands of Levofloxacin. Asian J Pharm Biol Res 2011, 1(2):174-181.
49. Patil MVK, Kandhare AD, Bhise SD Evaluation of patient information leaflets on basis of consumer psychology and opinion. Int J Phar Pharm Sci Res 2011, 1(2):87-92.
50. Schiff M, Bessette L Evaluation of abatacept in biologic-naïve patients with active rheumatoid arthritis [includes some 2-year data from ATTEST trial]. Clin Rheumatol 2010, 29:583-591.
51. Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011, 70:583-589.
52. Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DP, Ashcroft DM Effectiveness of Rituximab in Patients with Rheumatoid Arthritis: Observational Study from the British Society for Rheumatology Biologics Register. J Rheumatol 2012, 39:240-246.
53. Valleala H, Korpela M, Mottonen T, Hienonen-Kempas T, Kauppi M, Hannonen P, et al. Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients. Scand J Rheumatol 2009, 38:323-327.
54. Grandy S, Fox KM EQ-5D visual analog scale and utility index values in individuals with diabetes and at risk for diabetes: Findings from the Study to Help Improve Early evaluation and management of risk factors leading to diabetes (SHIELD). Health Qual Life Outcomes 2008, 6:18.
55. del Pozo-Cruz B, Hernández Mocholí MA, Adsuar JC, Parraca JA, Muro I, Gusi N Effects of whole body vibration therapy on main outcome measures for chronic non-specific low back pain: a single-blind randomized controlled trial. J Rehabil Med 2011, 43:689-694.
56. Luo N, Cang SQ, Quah HM, How CH, Tay EG The discriminative power of the EuroQol visual analog scale is sensitive to survey language in Singapore. Health Qual Life Outcomes 2012, 10:32.
57. Scott DL, Antoni C, Choy EH, van Riel PLCM Joint counts in routine practice. Rheumatol (Oxford) 2003, 42:919-923.
58. Arya V, Malaviya AN, Raja RR CDAI (Clinical Disease Activity Index) in rheumatoid arthritis: cut-off values for classification into different grades of disease activity. Ind J Rheumatol 2007, 2:91-94.
59. Ghosh P, Bodhankar SL Association of smoking, alcohol and NSAIDs use with expression of cagA and cagT genes of Helicobacter pylori in salivary samples of asymptomatic subjects. Asian Pac J Trop Biomed 2012, 2(6):479-484.
60. Sharma R, Thakare M, Thomas J, Agrawal S, Rajasekhar L, Narsimulu G Simplified Disease Activity Index as an index of disease activity in patients with rheumatoid arthritis: a comparison with DAS28. Ind J Rheumatol 2009, 4:11-14.
61. Solomon DH, Love TJ, Canning C, Schneeweiss S Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. Ann Rheum Dis 2010, 69:2114-2117.
62. Finckh A, Ciurea A, Brulhart L, Moller B, Walker UA, Courvoisier D, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?. Ann Rheum Dis 2010, 69:387-393.
63. Happonen KE, Saxne T, Geborek P, Andersson M, Bengtsson AA, Hesselstrand R, et al. Serum COMP-C3b complexes in rheumatic diseases and relation to anti-TNF-α treatment. Arthritis Res Ther 2012, 14(1):R15.
64. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010, 69:325-331.
65. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The Diagnostic Properties of Rheumatoid Arthritis Antibodies Recognizing a Cyclic Citrullinated Peptide. Arthritis Rheumatism 2000, 43:144-163.
66. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 american college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012, 64:625-639.
67. Makrygiannakis D, Hermansson M, Ulfgren AK, Nicholas AP, Zendman AJ, Eklund A, et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis 2008, 67:1488-1492.
68. Nandakumar KS, Jansson A, Xu B, Rydell N, Blom AM, Holmdahl R A recombinant vaccine effectively induces c5a-specific neutralizing antibodies and prevents arthritis. PloS One 2010, 5:e13511.
69. Ghosh P, Pandit VA, Karandikar Y, Diwan AG, Bodhankar SL A cross sectional study to determine risk factors associated with prevalence of H. pylori infection in salivary samples of acid peptic disease patients in western India. Pharmacologia 2012, 3(11):554-564.
70. Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T Transmembrane TNF-α: structure, function and interaction with anti-TNF agents. Rheuamtology (Oxford) 2010, 49:1215-1228.
71. Ghosh P, Kandhare AD, Raygude KS, Gauba D, Gosavi TP, Bodhankar SL Cigarette smoking and H. pylori infection: A meta-analysis of literature. Der Pharmacia Lettre 2012, 4(1):128-134.
72. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975.
73. Gosavi TP, Ghosh P, Kandhare AD, Bodhankar SL Unwrapping Homeopathic Principles in the Wake of Research: Serendipity, Placebo or True Therapeutic Milestones. Pharmacologyonline 2011, 1:894-906.